Grifols receives FDA approval of Erytra Eflexis, the latest advancement in scalable blood typing solutions
BARCELONA, Spain: Grifols, a leading producer of plasma- derived medicines and recognized leader in transfusion medicine, has received U.S. Food and Drug Administration approval of Erytra Eflexis, a fully automated, benchtop analyzer. The system performs pretransfusion compatibility testing using DG Gel technology.
Grifols' dedication to developing and distributing improved diagnostic solutions has been exceptionally successful this year, said Carsten Schroeder, President of Grifols Commercial Diagnostic Division. Erytra Eflexis marks our seventh FDA diagnostic approval so far in 2018, and it's the third approval for our expanding blood typing portfolio. And, feedback from the European medical community continues to be positive since receiving the CE Mark in June 2017.
Erytra Eflexis incorporates two lab configurations in a single instrument so laboratories can select the solution best suited to various workflow needs and capacities. This smart, flexible and intuitive system optimizes workflow efficiency and improves daily workloads, providing laboratories with a high level of flexibility and adaptability. It's designed for enhanced quality control to support improved patient care.
Interchangeable sample and reagent linear racks allow easy, continuous loading of cards, reagents and samples. A benchtop, compact model, Erytra Eflexis features real random access with a capacity of up to 200 cards, 72 samples and 46 liquid reagents. The transparent casing provides a clear view of the simple internal organization and processes.
For more information about Grifols Diagnostic Solutions, visit diagnostic.grifols.com.